Deciphering the mechanistic underpins of the inflammation-to-proliferation phase transition in human skin wound healing
Grantee: Ning Xu Landén, Associate Professor, Karolinska Institutet
Amount: DKK 4,164,510
Grant category: Research Grants in open competition
Year: 2022
Geography: Sweden
Ning Xu Landén’s project seeks to improve wound healing by identifying key regulators of cellular transition from inflammation to proliferation, a cardinal event during normal skin wound healing which is lacking in chronic wounds.
Ning and her team will approach this by mapping the spatiotemporal changes, both genetic, molecular and cellular, happening during the healing of acute wounds. Using this mapping, she and her team will then aim to identify the core genetic changes and intercellular crosstalk which regulates the inflammation to proliferation transition. Once identified, these changes and intercellular crosstalk will be characterized in more detail.
The ultimate goal is to identify the “master” regulators of inflammation-to-proliferation transition in order to improve and accelerate wound healing and thus minimize the risk of development of chronic wounds.
If successful, this project could pave the way for a novel approach to wound healing which may also eventually reduce subsequent scarring.
New therapy and diagnostics of psoriasis vulgaris and psoriatic arthritis based on new animal models
Grantee: Rikard Holmdahl, Professor, Karolinska Institutet
Amount: DKK 3,622,500
Grant category: Research Grants in open competition
Year: 2022
Geography: Sweden
Rikard Holmdahl and his team have discovered that mannan, a large natural sugar molecule found in yeast and plant cell walls, can induce a psoriasis-like condition in mice which strongly resembles human disease in terms of both genetics and clinical presentation.
The aim of Rikard’s research is to investigate the potential of this animal model to improve our understanding of disease mechanisms, predict disease progression and potentially treat psoriasis and psoriatic arthritis by modifying the sugar structure of mannan – hereby increasing the cellular level of reactive oxygen species which appears to be protective against disease development and progression.
In addition, Rikard’s team aims to identify new diagnostic (auto-)antibodies, found both in the mannan-induced psoriasis (MIP) mouse model and in a cohort of psoriatic arthritis patients, to improve early diagnosis and hence improve intervention.
If successful, the results could provide a new and more exact tool to further investigate what causes psoriasis and psoriasis arthritis, while at the same time potentially improving the efficiency of early diagnosis and subsequent treatment.